PD Adequest software is a powerful, Windows-based tool created to measure, report, and predict the adequacy of PD prescriptions for individual patients. PD Adequest software combines sophisticated data management and predictive modeling technologies into one easy-to-use clinical application.
A broad-based clinical study was completed in 1998 with the purpose of clinically validating the use of the PD Adequest software computer kinetic model. This validation, carried out by the PD Adequest International Study Group following a protocol developed by Baxter Healthcare Corporation, assessed the level of agreement between measured and predicted values of urea Kt/V, creatinine clearance (Ccr L/week/1.73m2), glucose absorption (GA g/day) and ultrafiltration (UF L/day) for both CAPD and APD prescriptions. This was an international, multicenter study of 104 adult PD patients (41 CAPD, 63 APD) in 16 centers. Measured (M) and predicted (P) values of Kt/V, Ccr, GA and UF were compared using correlations (r), concordance correlations (rc) and Bland-Altman limits of agreement. Measured values were obtained from three repeat 24 hour urine and dialysate collections while predicted values were independently modeled using the Baxter PD Adequest software in combination with patient-specific parameters estimated from a 4 hour peritoneal equilibration test (PET) and long-dwell exchange.
Overall results indicate PD Adequest software can predict Kt/V, Ccr, and GA with reasonable accuracy. For CAPD there was good agreement between predicted and measured UF values, and moderate agreement between predicted and measured UF values for APD.
